Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE

NCT04373707 is registered in ClinicalTrials.gov with Central Hospital, Nancy, France as lead sponsor.

NCT NCT04373707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04373707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE
Lead sponsor
Central Hospital, Nancy, France
Phase
Phase 4
Overall status
Completed
Start date
May 13, 2020
Completion date
September 14, 2021
Enrollment
1,000 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid, deep vein thrombosis, pulmonary embolism, thrombosis